Clinical Supply–Why Putting Patients First Matters
The time to stop hammering square pegs into round holes in terms of design strategy has come, as sponsors embrace an adaptive supply chain approach.
The growing volume of clinical studies and the increasing ‘need for speed’ is symptomatic of a highly competitive biopharmaceutical marketplace. When coupled with the emergence of biologics,predicted to grow at a CAGR of 9.7 percent between 2016 and 20211, it becomes apparent that over the last decade drug development has evolved and will continue to do so.
